A Phase II, Open-Label, Multi-Center, Prospective, Randomized Study of LCP-Tacro Tablets vs. Azathioprine, in Combination With Corticosteroids, for the Treatment of Autoimmune Hepatitis
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 13
- 试验地点
- 12
- 主要终点
- Biochemical Remission of (AIH) at Month 6.
研究概览
简要总结
An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine, each in combination with prednisone, for the treatment of autoimmune hepatitis (AIH).
详细描述
An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine for the treatment of autoimmune hepatitis (AIH).
Patients with histologically confirmed chronic hepatitis who fulfill criteria established by the International Autoimmune Hepatitis Group (IAIHG) and Inclusion and Exclusion criteria will be enrolled after having signed an informed consent document.
Up to 60 patients will be randomized (1:1) to receive treatment with LCP-Tacro + prednisone vs. azathioprine (AZA) + prednisone.
- LCP-Tacro will be started at 2 mg once daily (q.d.) with weekly measurement of tacrolimus whole blood trough levels and adjustment of the daily dose of LCP-Tacro to achieve target tacrolimus levels of 3 - 6 ng/mL. Patients with histological evidence of cirrhosis and a Model for End-Stage Liver Disease (MELD) score ≤ 8 will commence LCP-Tacro at a fixed dose of 1 mg once daily, with subsequent dosage adjustments to maintain tacrolimus trough levels at 3 - 6 ng/mL.
- AZA will be started at 50 - 100 mg (approximately 1 mg/kg) once daily (q.d.).
Patients will also commence treatment with prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women at least 18 years of age with a diagnosis of definite or probable AIH defined by the revised International Autoimmune Hepatitis Group (IAIHG) criteria
- •Elevation of serum ALT ≥ 1.5 times the upper limit of normal
- •Liver biopsy showing chronic hepatitis consistent with AIH
- •Patients able to swallow the study medication
- •Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study
- •Women of childbearing potential must have a negative serum pregnancy test within seven days prior to receiving study medication and agree to use contraceptive measures to avoid pregnancy during participation in the trial.
排除标准
- •Patients with other concurrent liver disease
- •Patients with cirrhosis on liver biopsy with a MELD score > 15
- •Patients with a history or presence of decompensated liver disease
- •Patients with serum creatinine ≥ 1.5 mg/dL prior to enrollment
- •Patients positive for HCV RNA or Hepatitis B surface antigen (HBsAg)
- •Patients with a history of alcohol intake > 25 g/day within the past six months
- •Patients with TSH outside normal range accompanied by an abnormal T4
- •Patients with alpha-fetoprotein ≥ 20 ng/mL
- •Patients with severe anemia (hemoglobin < 8 g/dL), leukopenia (WBC < 4000/mm3), or thrombocytopenia (platelet count < 100,000/mm3)
- •Patients with a history of recent exposure to hepatotoxic drugs
- •Patients who require therapy with any immunosuppressive agent other than those prescribed in the study
- •Patients unable or unwilling to provide informed consent
- •Pregnant or nursing women
- •Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception
- •Patients who have been treated with another investigational agent in the three months prior to enrollment
- •Patients receiving any drug interfering with tacrolimus metabolism
- •Patients with current malignancy or a history of malignancy (within the past 5 years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully
- •Patients with uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives
- •Patients with severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus
- •Patients with a known hypersensitivity to azathioprine, corticosteroids or tacrolimus
- •Patients with any form of current substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator
- •Patients who are recipients of an organ transplant or who require treatment with immunosuppressives or corticosteroids for any disease other than AIH.
研究组 & 干预措施
LCP-Tacro
LCP-Tacro tablets(1,2,and 5mg tacrolimus)+ prednisone tablets(5mg)
干预措施: LCP-Tacro (tacrolimus) (Drug)
Azathioprine
Azathioprine tablets(50mg)+ prednisone tablets(5mg)
干预措施: Azathioprine (Drug)
结局指标
主要结局
Biochemical Remission of (AIH) at Month 6.
时间窗: 6 months
Percent of patients that achieve biochemical remission of (AIH) at Month 6 during treatment with LCP-Tacro + prednisone or azathioprine + prednisone. Biochemical remission is defined as ALT, total bilirubin and gamma globulin within normal limits.
次要结局
- Biochemical Remission by Month 3.(3 months)
- Incomplete Response, Treatment Failure, or a Case of Relapse at 6 Months(6 months)